Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$56.69 USD
+0.73 (1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $56.66 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRNX 56.69 +0.73(1.30%)
Will CRNX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Other News for CRNX
StemPoint Capital LP Increases Stake in Surrozen Inc
Crinetics Pharmaceuticals: Strong Buy Recommendation Driven by Best-in-Class Efficacy and Solid Financial Position
State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
3 Best Stocks to Buy Now, 10/15/2024, According to Top Analysts
Crinetics Pharmaceuticals (CRNX) Gets a Buy from Piper Sandler